Allergy Therapeutics Share Discussion Threads

[jpuff] 17/9/2021 17:48

CFO presentation on 28th September, AJ Bell investment webinar

[coinbase] 17/9/2021 16:26

Place your bets, this is only going one way and that is up!

[farmergeorge] 16/9/2021 18:47

Very encouraging jimmyloser, thanks.

[jimmyloser] 16/9/2021 18:26

This is todays Non RNS. The last paragraph is well worth digesting (impo)

Allergy Therapeutics PLC

16 September 2021

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

ImmunoBON voted Most Innovative Product of 2021 at Pharma Trend Image and Innovation Awards in Germany

16 September 2021 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, is pleased to announce that ImmunoBON, the Group's patented protein-based oral product for the general treatment of allergies, has been voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation Awards in Germany.

The awards, held every year, are based on the Pharma Trend benchmark study, which seeks the views of 700 physicians, 100 pharmacists and 600 patients in Germany.

ImmunoBON, which Allergy Therapeutics launched in Germany and Austria earlier this year, replicates the reduced allergic reactions seen in people who live on or close to livestock farms - the so called 'farm effect'. It offers an innovative treatment approach for patients with mild allergies, the largest segment of the allergy market.

Latest data support its use as a treatment for birch and house dust mite allergies and Allergy Therapeutics is currently exploring its potential across a broader patient population.

Manuel Llobet, CEO of Allergy Therapeutics , stated: "We are delighted that ImmunoBON has been recognised for its innovative approach to the treatment of allergy patients, particularly as the award is voted for by those we serve - doctors, pharmacists and patients.

"ImmunoBON is an exciting product that provides an over the counter (OTC) option which fits very well with our portfolio philosophy to develop highly differentiated products with specific value added for our patients. Following successful launches in Germany and Austria, we are looking forward to making ImmunoBON available to more patients, through additional country launches, and through research exploring its potential to treat additional allergies".

[jimmyloser] 16/9/2021 06:15

More encouraging news from AGY this morning with ImmunoBon voted the most innovative new product of 2021Dyor

[red army] 13/9/2021 19:32

After 38p there's very little resistance to £1.

[jpuff] 13/9/2021 19:06

Me too after all this time

[q2u] 13/9/2021 15:40

Well I will be cross if we get taken out too cheaply!

[coinbase] 13/9/2021 15:01

Hostile bid!?

[farmergeorge] 13/9/2021 13:23

Trading volume constantly seems to be at low levels.

[wizzkid211] 13/9/2021 13:15

WAPPER AGY is destined for a takeover...

[wapper] 13/9/2021 06:26

AGY is destined for greater things I have no doubt at all.Peanut allergy hay fever relief : will hit £1 medium term . GLAH

[jimmyloser] 13/9/2021 06:05

Good news for those allergic to peanuts etc. Good news for AGY and it's talented team and good news for the faithful followers and believersCongratulations and Thanks AGYJl

[wapper] 13/9/2021 06:04

Excellent news

[hacklesrising] 09/9/2021 16:43

Agreed. V exciting
Pete

[wapper] 09/9/2021 06:04

Presentation available website Monday. Very exciting times.

[jimmyloser] 07/9/2021 18:10

I am truly impressed

[jimmyloser] 07/9/2021 07:03

Allergy Therapeutics PLC

07 September 2021

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics to host KOL webinar on VLP Peanut vaccine candidate

7 September 2021 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, today announces that it will host a webinar entitled 'VLP Peanut; a next generation peanut allergy immunotherapy', on Friday 17 September 2021 at 14.00 BST, 09.00 EDT.

The webinar will include an introduction from Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, and a feature presentation by key opinion leader (KOL), Dr. Mo Shamji, Reader in Immunology & Allergy at Imperial College London.

Dr. Shamji will summarise the findings of the Group's ex vivo VLP Peanut 001 biomarker study which, as announced on 3 August 2021, showed the hypoallergenic potential of the vaccine candidate, due to enter the clinic in Q1 2022.

Dr. Matt Heath, Principal Scientist at Allergy Therapeutics, will also provide an overview presentation on the Group's novel virus-like particle (VLP) technology.

The presentation will be followed by a live Q&A session and details can be accessed on the Group's website at . A replay of both will be made available on the website shortly after the event.

[wapper] 07/9/2021 06:28

Great company.All on track.Well done indeed .

[jimmyloser] 07/9/2021 06:10

In my mind this mornings RNS screams that both we and Imperial London are 101% certain about our VLP and Peanut product.Exciting indeed, even if there is a way to go.I expect several interested parties to be on that call.Well done AGY!Impo

[jimmyloser] 01/9/2021 12:08

Company website

[farmergeorge] 01/9/2021 12:07

23rd September is the next earnings report for the period ending June 2021.

[metis20] 01/9/2021 11:42

LSE financial diary has FY at 3 September

has FY at 23 September

2020 Prelims RNS was on 23 September